Abbvie to submit Genmab-developed cancer drug for EMA approval

According to the Danish firm, the injection cancer drug being developed through Genmab and Abbvie’s oncology partnership, will be on the EMA’s table for evaluation in the second half of 2022.

Photo: Joost Melis / Genmab / PR

Monday, Genmab announced that partner Abbvie will submit subcutaneous epcoritamab, a treatment for patients with relapsed diffuse large B-cell lymphoma, with the European Medicines Agency (EMA) in the second half of 2022, according to a press release.

In the beginning of July, the Danish biotech firm also announced that Abbvie would seek market authorization in the US during H2 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs